Form 4: Relay Therapeutics Executive Sells Shares to Cover Tax Obligations

Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 2,698 shares of common stock to cover income tax withholding obligations upon the vesting of restricted stock units.

Summary

• On July 29, 2024, Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 2,698 shares of Relay Therapeutics common stock at a price of $8.85 per share.
• The sale was executed to cover income tax withholding obligations related to the vesting of 9,072 restricted stock units (RSUs) on July 27, 2024.
• Bergstrom had no discretion over the sale, which was conducted in accordance with Relay Therapeutics' policies regarding RSU vesting.
• Following the transaction, Bergstrom beneficially owns 524,081 shares of Relay Therapeutics common stock, including 461,237 shares underlying RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects a routine transaction to cover tax obligations, which is a normal part of executive compensation. It doesn't suggest any particular positive or negative outlook for the company.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This sale appears to be routine, covering tax obligations related to RSU vesting, and doesn't necessarily indicate a change in the executive's confidence in the company.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but given the reason for the sale (tax obligations), the impact is likely to be minimal.

Key Dates